Revenues from Contracts with Customers

3 Months Ended

Sep. 30, 2022

Revenue from Contract with Customer [Abstract]

Revenues from Contracts with Customers

3. Revenues from Contracts with Customers

Contract Balances. Contract liabilities primarily relate to advances or deposits received from the Company’s customers before revenue is recognized. As of September 30, 2022 and June 30, 2022, contract liabilities of $0.1 million and $0.4 million, respectively were included in accrued liabilities in the consolidated balance sheet.

Revenues by Product Portfolio. Net revenue disaggregated by significant product portfolio for the three months ended September 30, 2022 and 2021 were as follows:

	Three Months Ended
	September 30,
	2022		2021
ADHD Portfolio	$	11,585	$	9,327
Pediatric Portfolio		6,558		3,798
Consumer Health Portfolio		9,003		8,014
Other		509		758
Consolidated revenue	$	27,655	$	21,897

Other consists of non-core products identified to be discontinued or divested including Cefaclor, Flexichamber, generic Tussionex, Tuzistra XR, and ZolpiMist. (see Note 7 – Goodwill and Other Intangible Assets).

Revenues by Geographic location. The following table reflects the Company’s product revenues by geographic location as determined by the billing address of customers:

	Three Months Ended
	September 30,
	2022		2021
	(In thousands)
U.S.	$	27,476	$	21,106
International		179		791
Total net revenue	$	27,655	$	21,897